Treatment of early and refractory dermatomyositis with infliximab: a report of two cases
Treatment of early and refractory dermatomyositis with infliximab: a report of two cases
复制标题
DOI：
10.1007/s10067-006-0325-z
复制
发表时间：
2007-07-01
影响因子：
3.4
通讯作者：
Espinoza, Luis R.
中科院分区：
文献类型：
--
作者：
Dold, Sylvia;Justiniano, Maria E.;Espinoza, Luis R.
特发性炎症性肌病是导致骨骼肌无力的最大的获得性和潜在的可治疗原因。这种疾病的三个主要群体是多发性肌炎(PM)、皮肌炎(DM)和包涵体肌炎。在大多数PM/DM病例中，皮质类固醇仍然是最初治疗的主要药物。尽管使用了现有的药物，但难治性疾病的治疗可能具有挑战性。我们报告了两名难治性糖尿病患者，他们接受了英夫利昔单抗治疗。我们描述他们的表现，临床病程，治疗和结果。
The idiopathic inflammatory myopathies embody the largest group of acquired and potentially treatable causes of skeletal muscle weakness. The three major groups of this disorder are polymyositis (PM), dermatomyositis (DM), and inclusion body myositis. Corticosteroids continue to be the mainstay of initial treatment in the majority of cases of PM/DM. The treatment of refractory disease can be challenging despite the utilization of the medications currently available. We report two patients with refractory DM who were treated with infliximab. We describe their presentation, clinical course, treatment, and outcomes.